In 238 patients with primary biliary cholangitis and moderate-to-severe itch, linerixibat improved itch over 24 weeks vs placebo (WI-NRS change −2·86 vs −2·15; difference −0·72, p=0·0013), but diarrhoea (61% vs 18%) and serious adverse events (12% vs 3%) were more common.
RCTn = 238
Hirschfield et al. Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial